Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting

INTRODUCTION: Long-acting injectable (LAI) antipsychotics were developed to increase medication adherence in patients with schizophrenia. The US Food and Drug Administration (FDA)-approved LAI dosing provides guidance regarding oral antipsychotic supplementation. Previous studies have concluded conc...

Descripción completa

Detalles Bibliográficos
Autores principales: Alastanos, Jennifer N., Paxos, Chris, Emshoff, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322819/
https://www.ncbi.nlm.nih.gov/pubmed/30627499
http://dx.doi.org/10.9740/mhc.2019.01.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322819/
https://www.ncbi.nlm.nih.gov/pubmed/30627499
http://dx.doi.org/10.9740/mhc.2019.01.018

Ejemplares similares